Continuing Nivolumab After Progression Improves Survival in RCC

The continuation of nivolumab after tumor progression in patients with advanced renal cell carcinoma in the CheckMate 025 trial was found to extend survival, according to data presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, held earlier this month in Chicago (abstract 4509).

Median overall survival was 28.1 months for patients who continued to receive treatment vs 15 months for patients who stopped treatment at progression. In this video Saby George, MD, of the Roswell Park Cancer Institute in Buffalo, New York, discusses these results.